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The epidermis is a barrier tissue that is exposed 
to the environment and susceptible to injury. 
Cooperation between epithelial cells, growth 
factors, chemokines, and inflammatory cells leads 
to rapid repair of most injuries. However, in­
creasing numbers of patients suffer from chro­
nic, nonhealing wounds (1). Although much is 
known about processes leading to effective tissue 
repair, the role of human epithelial–resident T 
cells in wound healing has not been examined. 
+ T cells are found in both the epidermis and 
dermis of human skin (2–4). In contrast to ro­
dents, there is also a major resident population 
of epidermal + T cells (5). Other than analy­
sis of their presence, little is known about these 
human skin–resident T cell populations. The T 
cell compartment in mouse epidermis is exclu­
sively composed of + T cells, with invariant 
TCRs designated as dendritic epidermal T cells 
(DETCs) (6). These cells are critical for tumor 
immunosurveillance (7), skin homeostasis (8), 
and wound repair (9). Identification of a hu­
man skin T cell equivalent with specialized 
wound healing properties would provide crucial 
insight into the mechanism of effective repair 
of acute wounds and elucidate new targets for 
therapeutic intervention in the treatment of 
chronic wounds. In this report, we show that 
human epidermal + and + T cells contrib­
ute to the effective healing of acute wounds 
and are functionally defective in patients with 
chronic wounds, demonstrating a previously 
unrecognized component of human epidermal 
wound healing.
RESULTS AND DISCUSSION
V1 and  TCR–bearing cells reside  
in normal human epidermis
Before examining a role for + and + T 
cells in wound repair and homeostasis, we first 
investigated the presence of T cell populations 
in healthy human epidermis. We used a classical 
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Epidermal T cells have been shown to play unique roles in tissue homeostasis and repair  
in mice through local secretion of distinct growth factors in the skin. Human epidermis 
contains both + and + T cells whose functional capabilities are not understood. We 
demonstrate that human epidermal T cells are able to produce insulin-like growth factor 1 
(IGF-1) upon activation and promote wound healing in a skin organ culture model. More-
over, an analysis of the functional capabilities of T cells isolated from acute versus chronic 
wounds revealed a striking difference. Both + and V1+ T cells isolated from acute 
wounds actively produced IGF-1, demonstrating that they are activated during tissue 
damage to participate in wound repair. In contrast, IGF-1 production could not be detected 
in T cells isolated from chronic wounds. In fact, skin T cells isolated from chronic wounds 
were refractory to further stimulation, suggesting an unresponsive state. Collectively, these 
results define a novel role for human epidermis–resident T cells in wound healing and 
provide new insight into our understanding of chronic wound persistence.
© 2009 Toulon et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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cells in peripheral blood express the V2 chain (10). Indeed, 
V1+ T cells, but not V2+ cells, were found in the dermis 
and epidermis of patient skin samples (unpublished data). We 
therefore used an anti­V1 antibody for the detection of + 
T cells resident in the skin. We detected a substantial number of 
V1+ T cells compared with + T cells in the epidermis and 
dermis compared with the blood, in which the  T cell popu­
lation is mainly composed of V2+ T cells (Fig. 1, A and C) 
(11). Cutaneous leukocyte antigen (CLA), the ligand for   
method to isolate T cells from the skin (3) that offered the ad­
vantage of separating epidermis from dermis, and the ability to 
study freshly isolated cells. This was especially useful for inves­
tigating growth factor production by T cells in wounded skin, 
a characteristic that might be affected by culturing the T cells 
or using skin explants (4). Epidermal and dermal T cells were 
studied and compared with peripheral T cells from healthy 
donors. It has been previously reported that + T cells in ep­
ithelial tissues primarily express the V1 chain, whereas + T 
Figure 1.  T cell distribution in human skin. (A) Epidermal- and dermal-resident + and V1+ T cells express high levels of CLA. Representative  
cytometry plots show gated populations from four-color immunofluorescence. Epidermal and dermal cells were stained with anti-CD3, CLA, , and V1 
antibodies and were compared with healthy blood. Live lymphocytes were gated according to forward and side scatter. The numbers denote the percent-
ages of gated cells from the live cell gate shown. (B) There is a significant difference in CLA expression between blood and epidermal T cells. There is no 
difference in terms of CLA expression between epidermal and dermal T cells. Histograms show the percentage of CD3+, CLA+, +, and V1+ cells in the 
blood, epidermis, and dermis of healthy donors. Results represent means of data ± SEM of four normal skin samples (epidermis and dermis) and five 
healthy blood samples. (C) The V1/ T cell ratio is significantly different between the blood and epidermis as well as between the epidermis and dermis. 
Plots show the ratio of + to V1+ T cells in the blood, epidermis, and dermis of individual healthy donors. Ratios were compared using a one-tailed 
unpaired Student’s t test. Horizontal bars represent means of the values from the different patients.JEM VOL. 206, April 13, 2009  745
BRIEF DEFINITIVE REPORT
cific for CD3 (5 µg/ml OKT3). After 2 d, T cell activation 
was measured by an increase in cell­surface expression of 
the IL­2 receptor  chain, CD25, on + and V1+ T cells 
by flow cytometry. We observed an up­regulation of cell­
surface CD25 expression by both + and V1+ T cells 
(Fig. 3 B), demonstrating activation of both T cells subsets. 
Significantly, addition of anti­CD3 accelerated the wound 
closure rate at an early stage (days 0–2) compared with un­
treated skin (Fig. 3 C). Collectively, these data indicate that 
TCR­specific activation of resident T cells promotes wound 
healing at an early stage.
To identify whether T cell–produced IGF­1 is responsible 
for the improved wound closure, we attempted to block T 
cell–mediated IGF­1 responses using IGF­1 receptor (IGF­1R) 
antibody after anti­CD3 stimulation in skin organ culture. 
Wound closure was measured between days 0 and 2, because 
the effect of T cell activation was maximal at this early stage. 
As shown in Fig. 3 D, anti­CD3 stimulation increases the   
rate of wound closure. Addition of an anti–IGF­1R antibody 
significantly blocks this effect, demonstrating that T cell–
  mediated wound closure is dependent on IGF­1.
E­selectin that is expressed by endothelial cells, is also present 
on dermal­resident T cells (4). We found that epidermal + 
and V1+ T cells express high levels of CLA compared with 
T cells isolated from the blood (Fig. 1, A and B). There was 
no significant difference between the epidermis and dermis 
in terms of CLA expression in the + and V1+ subsets 
(Fig. 1 B), whereas CD28 expression was limited to CLA+, 
CD3+, + T cells (not depicted). Overall, our results indi­
cate that human skin contains epidermal­resident + and 
+ T cells that have the potential to function in immune sur­
veillance in the skin.
Resident epidermal T cells produce insulin-like  
growth factor 1 (IGF-1)
We recently showed that mouse DETCs regulate skin ho­
meostasis through the secretion of IGF­1 (8), a member of 
the insulin family of growth hormones. IGF­1 is used by ke­
ratinocytes in the skin for epidermal development and main­
tenance (12). In human skin, IGF­1 regulates keratinocyte 
shape and migration for the mediation of wound epitheliali­
zation (13). Fibroblasts have been suggested to be the main 
IGF­1 source in the skin (14). To investigate whether human 
epidermal T cells can contribute to this aspect of wound re­
pair, human T cells were isolated from the epidermis of nor­
mal skin and assessed for IGF­1 production by flow cytometry. 
Skin from 17 healthy donors was examined. For each donor, 
epidermal cells were incubated with Brefeldin A for 6 h in 
the presence or absence of PMA and ionomycin. We found 
that epidermal + and V1+ T cells constitutively produce 
IGF­1 at low levels (Fig. 2), as previously described for mouse 
DETCs (8). Moreover, we observed a significant threefold 
increase of IGF­1 production by skin­resident T cells upon 
stimulation (Fig. 2 B). No correlation between donor age 
and IGF­1 production was observed (r < 0.8). Interestingly, 
previous studies have shown that levels of IGF­1 are increased 
after epidermal injury, peaking at 3 d after wounding (15), 
and IGF­1 in human wound fluid reaches maximum levels 
within 24 h after injury (16). Collectively, our results dem­
onstrate that human skin T cells are a previously unrecog­
nized local source of IGF­1 in the epidermis and have the 
capacity to up­regulate growth factor expression upon acti­
vation, which may affect wound repair.
Specific T cell stimulation promotes wound healing
To examine the participation of skin­resident T cells in the 
reepithelialization phase of wound repair, we used a well­
defined model of in vitro skin organ culture (16). Because 
human lymphocytes have not been studied in this model, 
we first showed that epidermal­resident T cells do not mi­
grate out of the skin during the first 2 d of culture, and 
demonstrated that + and V1+ cells remain functional 
upon in vitro stimulation by examining IFN­ production 
(Fig. 3 A). Next, we directly stimulated resident T cells in 
situ with an anti­CD3 antibody in skin organ cultures, as 
previously described for cells in the small intestine (17). 
Human skin was cultured with or without an antibody spe­
Figure 2.  Resident epidermal T cells produce IGF-1 upon stimula-
tion in vitro. (A) Flow cytometry of freshly isolated epidermal cells stimu-
lated with PMA and ionomycin, and stained with anti-IGF-1. (B) Statistical 
analysis of IGF-1 expression in normal epidermal T cells (n = 17). The pop-
ulation was distributed as follows: sex, 12 females and 5 males; age, 44.8 ± 
22.2 yr. There is a significant difference in IGF-1 expression before and 
after stimulation in the + and the V1+ subsets according to a one-
tailed Student’s t test. In all flow cytometry analyses, protein production 
was determined by subtracting the geometric mean fluorescence intensity 
(GMFI) of the control secondary antibody from the GMFI of cells treated 
with specific antibodies. Results represent means of data ± SEM.746 A ROLE FOR SKIN-RESIDENT T CELLS IN WOUND HEALING | Toulon et al.
have been shown to be decreased in nonhealing wounds 
from diabetic patients (18). We therefore hypothesized that 
skin­resident T cells are activated upon injury in vivo to pro­
duce IGF­1. We investigated IGF­1 expression in + and 
V1+ T cells from acute wounds. Skin specimens from   
patients suffering from recent injury were used to study IGF­1 
production in the context of acute wounds. Cells were iso­
lated from acute wounds and examined for IGF­1 produc­
tion by flow cytometry. Levels of IGF­1 produced by both 
+ and V1+ T cells from wounded skin were similar to 
IGF­1 levels in T cells stimulated with PMA and ionomycin 
(Fig. 4 B). In addition to PMA and ionomycin, anti­CD3–
stimulating antibody induced IGF­1 production in T cells, 
whereas IL­2 treatment did not (unpublished data). This data 
implies that T cells up­regulate IGF­1 in response to tissue 
injury, which likely promotes wound repair.
To determine if this is a unique response of skin­resident 
T cells during injury, + and V1+ T cells were isolated 
from the blood of both normal healthy donors and from 
acutely wounded patients 2–7 d after surgery. Basal IGF­1 
T cells are activated after acute injury but are functionally 
impaired in chronic wounds
Several pathogenic abnormalities contribute to failure to heal, 
and the progression of the healing process is impaired in 
chronic wounds. We therefore hypothesized that T cells might 
be reduced in number or functionally defective in patients af­
fected by chronic wounds. Skin samples (n = 8) from patients 
exhibiting wounds that had failed to heal within 8 wk were 
used to study the presence and function of T cells in chronic 
wounds, as compared with patients with acute wounds healing 
normally. No significant differences were found in the ratio of 
+ to V1+ T cells in chronic as compared with acute wounds 
(Fig. 4 A). Analysis of absolute cell numbers found an average 
of 2,890  and 283 V1 T cells/cm2 in normal epidermis, 
and an average of 10,860  and 300 V1 T cells/cm2 in acute 
and chronic wounds. These data suggest that there is a recruit­
ment of primarily  T cells to wound sites, whereas the V1 
T cells found in wounds are a skin­resident population.
One of the hallmarks of the early stage of wound repair 
is increased IGF­1 at the wound site, and levels of IGF­1 
Figure 3.  Rate of wound closure in organ culture is increased after activation of skin-resident T cells. (A) T cells remain responsive after 2 d of 
organ culture. Freshly isolated epidermal cells stimulated with PMA and ionomycin, and stained with IFN- for analysis by flow cytometry. IFN- expression 
was assessed on normal skin freshly harvested (day 0) and after being cultured for 2 d (day 2) on gelfoam in DMEM/10% FCS. Skin from the same donor was 
used for both day 0 and 2 analyses. Data are representative of three independent experiments. Percentages are shown. (B) Anti-CD3 stimulation activates 
skin-resident T cells in organ culture. The experiment was performed on skin cultured for 2 d on a gelfoam in DMEM/10% FCS in the presence or absence of 
anti-CD3 (5 µg/ml OKT3) antibody. Flow cytometry of freshly isolated + and V1+ T cells stained with CD25 is shown. Data are representative of three 
independent experiments. Percentages are shown. (C) The addition of stimulating antibodies to CD3 increased the rate of wound closure in skin organ culture. 
Analysis of skin wound closure kinetics in the presence (dashed line) or absence (continuous line) of an mAb to CD3. Data are presented as the means ± SD 
of three independent experiments with an average of three foreskins per experiment, and are representative of seven total experiments (with a sum of 20 
foreskins). (D) Blocking of T cell–mediated wound closure with IGF-1R antibody in skin organ culture. Data are the means ± SD of the slope of wound closure 
between days 0 and 2 of three independent experiments performed in triplicate. Data were compared using a one-tailed paired Student’s t test.JEM VOL. 206, April 13, 2009  747
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However, an analysis of the functional capabilities of T 
cells isolated from chronic versus acute wounds revealed a 
striking difference. Both + and V1+ T cells isolated from 
nonhealing  chronic  skin  wounds  did  not  produce  IGF­1 
compared with T cells isolated from acute wounds (Fig. 4,   
B and D). No significant differences were observed in CD69 
expression on  and V1 T cells from patients with chronic 
wounds (n = 4) compared with normal epidermis (n = 4; not 
depicted). This indicates that, although present, T cells in 
levels were similar between T cells isolated from the acutely 
wounded patients as compared with the normal healthy do­
nors. We observed a small but not statistically significant in­
crease in the wounded patients that may represent + or 
V1+ T cells that have exited the wound site. In all cases, 
IGF­1 levels were increased upon ex vivo stimulation with 
PMA and ionomycin. Our data suggests that up­regulated T 
cell production of IGF­1 during wound repair is limited to 
the local environment (Fig. 4 C).
Figure 4.  IGF-1 production by T cells in acute versus chronic wounds. (A) Ratio of  and V1 T cells in acute (n = 4) versus chronic (n = 8) 
wounds. Data were compared using a two-tailed unpaired Student’s t test. Horizontal bars represent means of the values from the different patients.  
(B) Cells were isolated from normal epidermis (top), acute wounds (middle), and chronic wounds (bottom) and examined for IGF-1 expression by flow 
cytometry. (top and bottom) Cells were also stimulated with PMA and ionomycin, and stained with anti–IGF-1. Cells isolated from acute wounds were  
not stimulated. The acute wound and the healthy epidermis shown were isolated from the same patient and were processed simultaneously. Data are 
representative of acute wounds obtained from four patients and chronic wounds obtained from eight patients. pt, patient. (C) IGF-1 production in circulat-
ing + and V1+ T cells isolated from the blood of healthy (H; n = 5) and acutely wounded (W; n = 4) patients before and after stimulation with PMA and 
ionomycin. (D) IGF-1 production is greatly enhanced in acute wounds as compared with chronic wounds and healthy epidermis. There is a significant dif-
ference in IGF-1 expression in the + and the V1+ subsets in acute wounds compared with normal epidermis and chronic wounds. Normal epidermis  
(n = 17), acute wounds (n = 4), and chronic wounds (n = 8) were examined in the absence of stimulation. Histograms show means ± SD. The GMFI of IGF-1 
production by + and V1+ cells is shown. In all graphs showing flow cytometry analysis, protein expression was determined by subtracting the GMFI  
of the control secondary antibody from the GMFI of cells treated with specific antibodies. Data are means ± SD.748 A ROLE FOR SKIN-RESIDENT T CELLS IN WOUND HEALING | Toulon et al.
that debridement, often an effective treatment for resolving 
chronic wounds, could aid in the release of trapped growth 
factors unavailable for wound healing. Moreover, the hypoth­
esis that debridement resets the stage for wounds proceeding 
toward the normal sequence of healing (20) is supported by 
patient 4 (Fig. 4 B) from our acute wound group. This patient 
received a first debridement surgery 3 d before our detection 
of high T cell specific IGF­1 production.
Cutaneous wound healing is a complex process requiring 
constant communication between cells in the form of cyto­
kine release, cell­to­cell contacts, and cell­to­matrix interac­
tions. Chronic wounds are a serious clinical problem affecting 
numerous elderly and diabetic patients. Many cell types are 
involved in wound healing, but the role of resident T cells 
has been neglected. This report demonstrates for the first 
time that skin­resident T cell populations (+ and V1+) are 
able to produce IGF­1, which can contribute to skin homeo­
stasis and promote wound healing. It will now be important 
to define the trigger of + and V1+ T cell activation in 
acute wounds and address the mechanism of dysregulation of 
T cell–mediated wound repair in chronic wounds. Some of 
chronic wounds are functionally impaired and are unable to 
produce IGF­1 during the tissue repair process.
Epidermal T cells from chronic wounds are less responsive  
to stimulation
To better characterize whether skin­resident T cells in chronic 
wounds retain the ability to produce IGF­1 and cytokines 
upon stimulation, we isolated + and V1+ T cells from the 
epidermis of normal and chronic wounds, and stimulated 
them in vitro for 6 h with PMA and ionomycin. As shown in 
Fig. 5 A, neither + or V1+ T cells isolated from chronic 
wounds could be restored by stimulation with PMA and ion­
omycin (Fig. 5 A). Additionally, + and V1+ T cells iso­
lated from chronic wounds produce significantly less IL­2 
after stimulation compared with cells isolated from normal 
epidermis (Fig. 5 B). This suggests that the T cells in a chronic 
wound environment become less responsive to activation.
Collectively, these data indicate that T cells are function­
ally impaired in chronic wounds, and bypassing TCR stimu­
lation is unable to rescue function. These data are in line with 
the hypothesis proposed by Falanga et al. (19), which states 
Figure 5.  IGF-1 and IL-2 production by T cells in normal epidermis and chronic nonhealing wounds. (A) IGF-1 production by + and V1+ T 
cells is significantly higher after stimulation in normal epidermis (n = 17) compared with chronic wounds (n = 8). Plots represent IGF-1 production by 
individual donors with or without stimulation with PMA and ionomycin. (B) The percentage of + (left) and V1+ (right) T cells producing IL-2 before 
and after stimulation with PMA and ionomycin in normal epidermis (n = 5) and nonhealing chronic wounds (n = 3). Although no difference in IL-2 pro-
duction by + and V1+ T cells in normal epidermis compared with chronic wounds was seen before stimulation, the percentage of + and V1+ cells 
producing IL-2 after stimulation is significantly lower in chronic wounds. Data were compared using a one-tailed unpaired Student’s t test. Horizontal 
bars represent means of the values from the different patients.JEM VOL. 206, April 13, 2009  749
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CD25 (0479) was purchased from Beckman Coulter. Analysis of flow cytom­
etry samples was performed on a FACSCalibur or an LSR­II (both from BD). 
Data were analyzed with FlowJo software (Tree Star, Inc.).
Skin organ culture. Skin organ culture was performed as previously de­
scribed (23) using human foreskin samples. This method can be effectively 
used to examine keratinocyte proliferation and migration during the reepithe­
lialization phase of wound repair. In brief, each sample was trimmed into four 
pieces with a 6­mm diameter each, and a punch biopsy with a 3­mm diameter 
including the epidermis and upper dermis was removed from the center. Each 
piece was placed with the dermis down on gelfoam (Savmart Pharmaceuticals) 
in a 24­well plate containing DMEM/10% FCS in the presence or absence   
of an anti­CD3 antibody (5 µg/ml OKT3; eBioscience) or the isotype   
control. These cultures were incubated at 37°C with 5% CO2 for 5 d, with 
the media changed every other day. For blocking experiments, 12 µg/ml 
IGF­1 receptor antibody (R&D Systems) was added to skin organ cultures. 
Digital images were acquired every day, and the wound surface area was 
measured and analyzed with ImageJ software (available at http://rsbweb.nih 
.gov/ij/). For each experiment, two to three foreskin samples were processed. 
To address T cell activation (CD25 expression and IFN­ production) after   
2 d of culture, healthy skin specimens were used and processed as described.
Statistical analysis. Data were analyzed using an unpaired Student’s t test to 
determine significant differences between two groups of patients and a paired 
t test to determine significant differences within the same group. Tests were 
two­tailed except when noted in the text. All findings were considered signif­
icant at P < 0.05. Power analysis based on previous mouse cell work indicated 
that a minimum sample size of two provided power of >95% at  = 0.05.
Online supplemental material. Table S1 shows the main features of the 
subjects with wounds presented in Fig. 4. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20081787/DC1.
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the healthy patients examined in this study did exhibit a low 
level of IGF­1 production by resident T cells after stimula­
tion. It is possible that this phenotype, in addition to chronic 
disease such as diabetes, increases susceptibility to chronic 
wounds. On the other hand, perhaps activating antigens are 
masked or overstimulate the T cells in a chronic wound, leading 
to their unresponsiveness to activation signaling. T cell dysfunc­
tion might also be caused by increased expression of inhibitory 
receptors such as programmed death 1, which have been shown 
to become elevated in response to severe injury (21) and HIV 
infection (22). From a clinical aspect, T cell impairment at an 
early stage of the wound healing process could be a predictive 
factor for chronic wound formation. In addition, these results 
may explain why wound debridement is often effective for the 
treatment of chronic wounds. This new evidence supports the 
idea that skin­resident T cells play a critical role in skin homeo­
stasis and the wound repair mechanism in humans, suggesting 
possible therapeutic targets that could be considered in the fu­
ture to enhance chronic wound management.
MATERIALS AND METHODS
Subjects. Acquisition of skin samples and all scientific studies were ap­
proved by the Institutional Review Boards of Scripps Health and the Uni­
versity of California, San Diego. Informed consent was obtained from all 
subjects. Samples of normal human skin and wounded skin were obtained 
from discarded human tissue from cutaneous surgery. Skin specimens from 
patients suffering from recent injury were used to study acute wounds. None 
of the patients had systemic disease or were currently receiving immuno­
suppressive treatment. Discarded tissue from patients affected by wounds that 
failed to heal within 2 mo was used to study chronic wounds. More details 
on patients enrolled in the study are given in Table S1. Foreskin was ob­
tained from the Cooperative Human Tissue Network for use in skin organ 
culture. Normal human blood was obtained from the Scripps Research In­
stitute Normal Blood Donor Services. Blood samples from patients after 
breast reduction surgery (2–7 d) were used to investigate IGF­1 production 
by T cells from acutely wounded patients.
Cell isolation. Separation of the epidermis and dermis was accomplished 
by floating small skin strips on 1.25 U/ml Dispase II solution (Roche) 
overnight at 4°C. Epidermal sheets were separated from the dermis by me­
chanical separation and vigorously agitated in fresh Dispase II for 30 min at 
37°C. The dermis was further treated with 1 mg/ml collagenase D (Roche) 
and Dispase II for 30 min at 37°C, isolating T cells from the dermis. 
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